Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRHm1-TT peptide as the main active principle; 245 μg of the very small size proteoliposomes adjuvant (VSSP); and 350 μL of Montanide ISA 51 VG oil adjuvant. The aim of this study was to assess the safety and tolerance of the He...

Full description

Bibliographic Details
Main Authors: Jesús A. Junco, Ranfis Rodríguez, Franklin Fuentes, Idania Baladrón, Maria D. Castro, Lesvia Calzada, Carmen Valenzuela, Eddy Bover, Eulogio Pimentel, Roberto Basulto, Niurka Arteaga, Angel Cid-Arregui, Francisco Sariol, Lourdes González, Liliana Porres-Fong, María Medina, Ayni Rodríguez, A. Hilda Garay, Osvaldo Reyes, Matilde López, Lourdes de Quesada, Allelin Alvarez, Carolina Martínez, Marleny Marrero, Guillermo Molero, Alfredo Guerra, Pedro Rosales, Carlos Capote, Sahily Acosta, Idania Vela, Lina Arzuaga, Ana Campal, Erlán Ruiz, Elier Rubio, Pável Cedeño, María Carmen Sánchez, Pedro Cardoso, Rolando Morán, Yairis Fernández, Magalys Campos, Henio Touduri, Dania Bacardi, Indalecio Feria, Amilcar Ramirez, Karelia Cosme, Pedro López Saura, Maricel Quintana, Verena Muzio, Ricardo Bringas, Marta Ayala, Mario Mendoza, Luis E. Fernández, Adriana Carr, Luis Herrera, Gerardo Guillén
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Oncology
Subjects:
advanced prostate cancer
GnRH/LHRH vaccine
hormone ablation
hormone sensitive cancer
overall survival
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00049/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00049/full

Similar Items